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Pituitary carcinoma: Two case reports and review of literature
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Pituitary carcinoma is a rare type of malignancy that can be very difficult to
diagnose and treat. Many cases were diagnosed at autopsy. Delays in diagnosis
often adversely impact patients' outcomes. Even with prompt diagnosis,
treatment decisions remain challenging in the absence of randomized controlled
trials.
CASE SUMMARY
We report two cases of pituitary carcinoma in men with a history of pituitary
adenoma. In the first case, a 55-year-old man was initially diagnosed with
pituitary macroadenoma. He underwent subtotal debulking of the tumor
followed by adjuvant radiotherapy. Subsequently, he developed relapsed disease
and multifocal intracranial metastases and a diagnosis of pituitary carcinoma was
rendered. He passed away despite several lines of systemic therapies including
temozolomide, lomustine and bevacizumab. Another 52-year-old man was
diagnosed with atypical pituitary adenoma with presentation of sudden onset of
vision loss in the right eye. He had recurrent pituitary carcinoma with spinal
metastases, treated with surgery, radiation and temozolomide.
CONCLUSION
Pituitary carcinoma is a rare neoplasm with poor prognosis that is difficult to
diagnose and treat. The small number of cases restricts our ability to design
randomized clinical trials. Management is largely driven by retrospective studies
and case series. Establishing molecular biomarkers and comprehensive genomic
profiling could help in decisions about diagnosis and management of pituitary
carcinoma.
Key words: Pituitary carcinoma; Diagnosis; Treatment; Pituitary adenoma;
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Core tip: Pituitary carcinoma is a rare type of malignancy that can be very difficult to
diagnose and treat. Many cases were diagnosed at autopsy. Delays in diagnosis often
adversely impact patients' outcomes. Even with prompt diagnosis, treatment decisions
remain challenging in the absence of randomized controlled trials. Establishing
molecular biomarkers and comprehensive genomic profiling could help in decisions
about diagnosis and management of pituitary carcinoma.
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Pituitary carcinoma is a rare type of malignancy defined as non-contiguous spread of
pituitary adenoma. Many cases were diagnosed at autopsy[1]. In contrast to benign
pituitary  adenoma,  which  is  one  of  the  most  common  intracranial  tumors,
representing 10%-15% of intracranial neoplasms[2], pituitary carcinoma accounts for
only 0.1%-0.2% of all pituitary tumors. It can present at any age but appears more
frequently in the third to fifth decade of life in patients with preexisting pituitary
adenoma. It is associated with dismal prognosis and has no standardized treatment
options.  The  median  survival  for  patients  with  pituitary  carcinoma,  before
temozolomide (TMZ) was introduced to the treatment algorithm, was about 2 years[3].
This number has probably improved after the first reported case using TMZ in 2006;
in one meta-analysis including a total of 54 patients, estimated 5-year survival was
57.4% for patients with atypical pituitary adenoma and 56.2% for those with pituitary
carcinoma[4]. The rarity of the disease limits the design of clinical trials to study the
tumorigenesis  and management.  Herein,  we present  two patients  with pituitary
carcinoma. Both received surgery, radiation and systemic therapies including TMZ.
We hope, by sharing our experiences on this rare condition, we will help advance
clinicians' recognition and management of this rare cancer.
CASE PRESENTATION
Chief complaint
Case 1: A 55-year-old male presented in September 2010 with a low testosterone level
and decreased vision in the left eye.
Case 2: A 52-year-old male presented with sudden vision loss in the right eye in April
2010.
History of present illness
Case 1: The symptoms started several months prior to presentation and have been
progressing gradually.
Case 2: Sudden vision loss without headache or neurological symptoms.
History of past illness
Case 1: History of clear cell renal cell carcinoma (CCRCC, stage II, T2N0M0), status
post right nephrectomy in 2009.
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Physical examination
Case 1: Unremarkable with the exception of mild decreased vision acuity in the left
eye.
Case 2: Profound vision acuity in the right eye.
Laboratory examination
Case 1: Normal complete blood count (CBC), Comprehensive metabolic panel (CMP),
decreased total serum testosterone.
Case 2: Normal CBC, CMP.
Imaging examination
Case 1: Magnetic resonance imaging (MRI) of the brain showed a 3.4 cm × 2.0 cm × 2.6
cm homogeneously enhancing mass in the sella with extension into the suprasellar
cistern and right side of the sphenoid sinus (Figure 1A).
Case 2: MRI of the brain showed a suprasellar mass invading the optic chiasm and
enveloping the carotid siphon and cavernous sinus (Figure 2A).
Case continued
Case 1:  The patient was diagnosed with pituitary macroadenoma and started on
hormone replacement  therapy for  secondary hypogonadism.  He underwent  left
frontotemporal  craniotomy with subtotal  resection in  February 2011.  Pathologic
examination yielded the diagnosis “atypical pituitary adenoma”, substantiated by a
Ki-67 labeling index (LI) of 13%; the resected material showed no immunoreactivity
for anterior pituitary hormones, and only weak immunoreactivity for p53 (Figure 3A).
He then completed a course of adjuvant intensive modulated radiotherapy to 54 Gy,
concluded in June 2011. In late 2011, the patient developed right visual loss secondary
to post-radiation optic neuritis. The residual tumor remained stable (Figure 1B) on
surveillance MRI studies until 2014.
Unfortunately,  brain MRI in April  2014 showed significant enlargement of the
tumor, with extension into the suprasellar region and left cavernous sinus (Figure 1C).
He  underwent  transsphenoidal  resection.  Pathologic  examination  revealed
histomorphologic features similar to those of the previous specimen; nuclei reactive
for p53 remained rare, but the Ki-67 LI had increased to 17%. A diagnosis of recurrent
atypical  pituitary adenoma was rendered (Figure 3B).  The patient  then received
adjuvant gamma knife radiosurgery to 30 Gy in 5 fractions.
In May 2015, the patient presented with confusion and focal seizures. Brain MRI/
magnetic resonance angiography showed interval development of a multiloculated
hemorrhagic  collection  around  an  enlarging  dural  enhancing  lesion  in  the  left
frontotemporal convexity, adjacent to the patient’s prior craniotomy site (Figure 1D).
A  whole  body  18F-FDG-positron  emission  tomography/computed  tomography
(PET/CT)  study  showed  increased  FDG  uptake  within  the  enhancing  left
frontotemporal dural lesion. The patient underwent left temporal craniotomy with
gross  total  resection  of  the  tumor,  described  intraoperatively  as  grayish-white,
gelatinous, and epidural. Histologic analysis, which included comparisons to the
patient’s  prior  specimens,  supported a  diagnosis  of  recurrent  atypical  pituitary
adenoma (Figure 3C). Ki-67 LI was calculated to be 25.5% and p53 stain was negative.
MGMT  (O-6-Methylguanine-DNA  Methyltransferase)  promoter  methylation,
evaluated upon clinical request, was not detected. The features of rapid growth, local
invasion, and markedly high Ki-67 LI are considered consistent with a “clinically
aggressive” adenoma; the additional finding of dissemination from the original sellar
region  technically  completes  clinicopathologic  diagnostic  criteria  for  pituitary
carcinoma.
Case  2:  The  patient  underwent  right  frontal  craniotomy  with  orbitozygomatic
osteotomy and subtotal resection of tumor in May 2010, at an outside institution.
Histologic analysis,  initially performed at Mayo Clinic in consultation, yielded a
diagnosis  (later  confirmed  at  our  institution)  of  atypical  pituitary  adenoma,
corticotroph type, with marked pleomorphism and increased mitotic activity, ranging
up to at least 5 per 10 high power fields (Figure 4A). The resection material showed no
intra-tumoral Crooke hyaline change to suggest a diagnosis of Crooke cell adenoma.
The patient subsequently received adjuvant Cyber Knife radiosurgery to a dose of 25
Gy in 5 fractions, completed in August 2010.
He was doing well  with no evidence of  progression until  surveillance MRI in
October 2015, which demonstrated interval development and growth of multiple right
extra-axial  cystic  paramedian  frontal  lobe  masses.  He  underwent  right  frontal
craniotomy with resection of a 2 cm right frontal brain lesion in February 2016 at the
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Figure 1
Figure 1  Radiographic images of the pituitary carcinoma discussed in case 1. A: Magnetic resonance imaging (MRI) in September 2010 shows a 3.4 cm × 2.0
cm × 2.6 cm enhancing sellar mass (arrow); B: MRI in April 2013 shows stable residual sellar lesion post-surgery and radiation (arrow); C: MRI in April 2014 shows
enlarging lesion extending to the suprasellar region and left cavernous sinus (arrow); D: MRI/Magnetic Resonance Angiography in May 2015 shows multiloculated
hemorrhagic collection around an enlarging dural enhancing lesion (arrow); E, F: MRI in August 2016, in comparison to MRI in March 2016, shows more enhancing
solid appearing sellar mass with interval enlargement of the tumor burden along the left cavernous sinus and middle cranial fossa.
same outside institution.  Subsequent pathology review of the resection material,
performed at our institution in parallel with a review of the 2010 resection material,
noted strong histomorphological similarities and strong reactivity for synaptophysin,
and yielded the diagnosis “metastatic atypical pituitary adenoma (atypical pituitary
carcinoma)” (Figure 4B). Follow up brain MRI in June 2016 showed recurrence of the
right frontal lesion as a 2.3 cm mass (Figure 2B); it also showed residual but stable
enhancing tissue within the sella turcica (not shown).
In October 2016, he was referred to our institution for a second opinion on further
medical management. MRI of brain and total spine (October 2016, Figure 2C and D)
showed stable enhancing pituitary tumor with bilateral cavernous sinus invasion and
intradural extramedullary metastatic tumor within the ventral spinal canal at T1-T3
and the T5 levels, causing severe spinal canal stenosis at T2-T3. T1-T4 decompression
and tumor resection was performed on November 4th,  2016. The spinal mass was
shown to be metastatic pituitary carcinoma, corticotroph subtype with reactivity for
adrenocorticotropic  hormone  (ACTH)  and  synaptophysin,  no  significant
immunoreactivity  for  p53,  and  a  Ki67  LI  of  approximately  4.8%  (Figure  4C-F);
histomorphological  features were considered essentially identical  to those of the
patient’s prior specimens.
FINAL DIAGNOSIS




The patient received adjuvant proton radiotherapy to 40 Gy divided in 15 fractions in
July 2015. He then commenced adjuvant TMZ at 150 mg/m2 for 5 consecutive days
out of a 28-d cycle. The first 7 cycles were administered without major complications.
Cycle 8 was delayed due to the discovery of a thyroid nodule, subsequently removed
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Figure 2
Figure 2  Radiographic images of the pituitary carcinoma discussed in case 2. A: Magnetic resonance imaging
(MRI) in April 2010 shows a suprasellar mass invading the optic chiasm and enveloping the carotid siphon and
cavernous sinus (arrow); B: MRI in June 2016 shows recurrence of a 2.3 cm right frontal lesion (arrow); C: MRI of
brain in October 2016 shows enhancing anterior right frontal lobe mass measuring 4.1 cm × 2.1 cm (arrow); D: MRI of
spine in October 2016 shows extramedullary metastatic tumor within the ventral spinal canal at T1-T3 levels (arrow,
T5 lesion is not shown here).
by  total  thyroidectomy in  February  2016.  Pathology  revealed  papillary  thyroid
carcinoma with metastasis to one of three lymph nodes (T3N1M0), as well as a focus
suspicious for c-cell hyperplasia. He was not treated with radioactive iodine given the
urgent need to resume chemotherapy. He resumed cycle 8 TMZ in April 2016. Shortly
thereafter,  he was noted to have a fast-growing right clavicle mass.  After biopsy
identified  this  mass  as  metastatic  RCC,  the  lesion  was  treated  with  stereotactic
radiation therapy with a total dose of 35 Gy delivered in 5 fractions. No systemic
treatment was given for his RCC. The patient continued 2 more cycles of TMZ. Brain
MRI in August 2016 revealed interval growth of the patient’s sellar mass since March
2016,  with  enlargement  along the  left  cavernous  sinus  and middle  cranial  fossa
(Figure 1E and F). Treatment was subsequently changed to lomustine (CCNU) at 110
mg/m2 once every 6 wk. CCNU was discontinued after 2 doses due to grade 3 fatigue
and a decline of Karnofsky performance status from 70% to 50%. We contemplated
the  ideas  of  comfort  measures  versus  alternative  treatment  options  including
bevacizumab.
Case 2
After tumor resection, the patient’s course was complicated by bacterial meningitis
with sphenoid erosion, cerebrospinal fluid leak and bacteremia, requiring a 3-wk
hospital stay. During the admission, endocrinology was consulted for hyponatremia
with  workup supporting  a  diagnosis  of  syndrome of  inappropriate  antidiuretic
hormone secretion. 8 AM cortisol level was not suppressed while the patient was on
dexamethasone  2  mg  every  8  h.  This,  together  with  an  ACTH-immunoreactive
pituitary carcinoma, raised concern for Cushing’s disease. Following the recovery and
completion of steroid tapering, further endocrine workup was conducted, including
low dose dexamethasone suppression test, late night salivary cortisol levels, and 24-h
urine free cortisol level. He was commenced on Pasireotide for confirmed Cushing’s
disease. He had secondary hypogonadism but refused testosterone replacement. He
received radiation to a total dose of 30 Gy to the intracranial lesions and additional 30
Gy to the C7 though T6 spine. In January 2017, he was started on monthly high-dose
TMZ chemotherapy (150 mg/m2 for 5 consecutive days on a 28-d cycle). TMZ was
initially planned for a total of 12 cycles. Brain MRI obtained prior to cycle 11 revealed
radiographically stable disease.
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Figure 3
Figure 3  Histological images of the pituitary carcinoma discussed in case 1. A: "Pituitary tumor" in 02/2011 showed an atypical pituitary adenoma with fairly
frequent mitotic figures (up to four per 10 high power fields), weak immunoreactivity for p53, and a Ki-67 labeling index of 13%; B: Recurrent "pituitary tumor" in
04/2014 also showed fairly frequent mitotic figures (up to two per 10 high power fields, no significant reactivity for p53, and a Ki-67 labeling index of 17%; C: The "left
convexity mass" in 05/2015 showed morphological features similar to those of the previously resected tissues, but with numerous mitotic figures (at least three per
most individual high power fields), a Ki-67 labeling index of 25.5%, and no reactivity for p53. Scale bar = 50 microns for all panels (400×).
OUTCOME AND FOLLOW-UP
Case 1
The patient eventually received two doses of bevacizumab (10 mg/m2, every 2 wk)
and then transitioned to hospice care. The patient expired in June 2017.
Case 2
After the 10th cycle of temozolomide, the patient decided to forego further treatment
and enrolled in  hospice  due to  a  decline in  performance status.  He expired two
months later.
DISCUSSION
Classification and diagnosis of pituitary tumors
Most pituitary adenomas are slow-growing and benign, with an estimated prevalence
in the general population to be 16.7%[5]. Pituitary carcinomas are rare neoplasms that
are defined by disseminated disease non-contiguous with the sellar region and/or
extraneural  metastases.  Until  recently,  the  World  Health  Organization  (WHO)
divided  pituitary  adenomas  into  three  categories:  (typical)  adenoma,  atypical
adenoma, and pituitary carcinoma; this classification system was revised in 2017[6].
The  term "atypical  pituitary  adenoma"  is  no  longer  recommended,  due  to  poor
reproducibility and predictive value.  The new classification designates pituitary
tumors based on adenohypophyseal  cell  lineages and focuses on prognostic  and
predictive values of histological and immunohistochemistry (IHC) markers; these IHC
markers may include pituitary transcription factors, but the validity of transcription
factors for this purpose is still under investigation. Tumor proliferation index and
radiological invasion are still emphasized to predict aggressiveness; the use of p53
IHC,  endorsed  by  some  published  reports  as  a  predictor  of  aggressiveness,  is
considered controversial, and is now endorsed by the new WHO guidelines only for
“limited” cases.
Histomorphologically, pituitary carcinomas are intrinsically indistinguishable from
pituitary adenomas. Consequently, appropriate classification of a lesion as “pituitary
carcinoma”  can  sometimes  be  challenging.  "Contiguous  spread"  versus  "non-
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Figure 4
Figure 4  Histological images of the pituitary carcinoma discussed in case 2. A: "Pituitary tumor" in 05/2010 showed an atypical pituitary adenoma with marked
pleomorphism and frequent mitotic figures (ranging up to five per ten high power fields); B: The "right frontal brain lesion tissue" in 10/2016 resembled the 2010
resection material from the pituitary; C-F: The spinal cord "intradural tumor" in 11/2016 resembled the previous two resection specimens, lacked significant
immunoreactivity for p53, exhibited a Ki-67 labeling index of approximately 4.8%, and showed diffuse immunoreactivity for adrenocorticotrophic hormone (arrows).
Scale bar = 100 microns for panels A and B (200 ×); Scale bar = 50 microns for panels C, D, E, F (400 ×).
contiguous spread" does not always provide clear diagnostic distinction. As described
in case 1,  the involvement of dura mater could potentially result from iatrogenic
“seeding”  during  previous  resections,  as  opposed  to  pathophysiological,  non-
contiguous spread from the pituitary adenoma. Although we cannot exclude this
potential etiology for case 1, we note that the patient's clinical course showed an
aggressive  pattern  in  parallel  with  the  neoplasm’s  elevated  proliferation  index.
Consequently, we interpret this case as consistent with pituitary carcinoma.
Pathogenesis
The pathogenesis of pituitary carcinoma is not entirely clear. Several models have
been  proposed  including  sequential  tumorigenesis  and  de  novo  transformation
models[7].  In  the  sequential  tumorigenesis  model,  the  development  of  pituitary
carcinoma follows a step-by-step transformation from non-adenomatous pituitary
cells to adenoma cells, then aggressive pituitary adenoma and/or pituitary carcinoma.
In the de novo transformation model, pituitary carcinoma cells metastasize from an
aggressive  pituitary  adenoma  that  originated  in  normal  pituitary  gland.  Most
researchers believe in the sequential tumorigenesis model with gradual accumulation
of genetic aberrations[8]; however, de novo development cannot be excluded based on
current knowledge. We noticed that the Ki-67 LI in case 1 appeared to rise with every
recurrence,  from  13%  to  17%  to  25.5%,  which  is  consistent  with  a  step-wise
transformation of the more aggressive type of pituitary neoplasm, or selection of a
fast-proliferating subpopulation under treatment pressure.
The presence of coexisting RCC (clear cell type) and papillary thyroid carcinoma in
the first patient certainly raised the question of an underlying germline mutation or a
cancer predisposing syndrome. Unfortunately, we did not obtain consent from the
patient for such molecular studies. There is literature linking pituitary carcinoma with
hereditary syndrome. Succinate Dehydrogenase Subunit B (SDHB)  mutation was
reported in one pituitary carcinoma case[9]. SDHB germline mutation carriers have a
high chance of developing paraganglioma/pheochromocytoma, and less frequently,
renal clear cell carcinoma and papillary thyroid carcinoma[10-12]. Among 910 Swedish
patients  with  germline  mutations  in  MMR (Mismatch  repair)  genes  (i.e.,  Lynch
syndrome),  3  developed pituitary tumors (a  higher prevalence than expected[13])
including one microprolactinoma, one invasive non-secreting macroadenoma, and
one pituitary carcinoma. In addition, patients with multiple endocrine neoplasia type
1  mutations  are  known to  be  at  risk  for  pituitary  adenoma as  well  as  pituitary
carcinoma[14].
Clinical presentation
Pituitary carcinomas can present clinically in three forms: As incidental findings
without symptoms; as functional endocrine neoplasms, with secretory symptoms
according to the type of hormone(s) secreted; or as mass lesions, with symptoms
(including but not limited to headache, visual changes or diplopia[15]) often caused by
the primary tumor. Most pituitary carcinomas are considered to be functional. The
most common types are prolactin- (PRL) secreting and ACTH secreting carcinomas[16].
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In  the  case  of  PRL-secreting  carcinomas,  female  patients  may  present  with
amenorrhea  and  galactorrhea;  males,  with  erectile  dysfunction[17].  Most  ACTH-
secreting tumors present with Cushing's disease[18], which was observed in Case 2.
Pituitary carcinomas that secrete growth hormone (GH) tend to present similarly to
benign GH-secreting adenomas; symptoms of acromegaly can occur[19]. Gonadotroph
and thyrotroph carcinomas are the rarest and they present like benign adenomas of
the same type[20,21].  There is  no clear  gender predilection,  although some reports
suggest that PRL- and ACTH-secreting carcinomas are more common in females[22].
Non- central nervous system (CNS) metastasis is more frequent than craniospinal
spread in pituitary carcinoma. The most common distant metastatic location is the
liver,  followed by bone, lung, and lymph nodes.  The interval between the initial
diagnosis  of  pituitary  adenoma  and  the  development  of  invasive  carcinoma  is
extremely variable,  ranging from 4 mo to 18 years (mean,  6.6  years;  median,  5.0
years)[22]. Pituitary carcinoma accounts for 0.1%-0.2% of all pituitary tumors and only
a few hundred cases  have been reported in  medical  journals[15,22,23].  Prognosis  of
pituitary carcinoma is generally poor, with overall survival of 2-4 years in patients
with CNS metastasis, and 12 mo in those with systemic metastasis[22,24-26].
Management
Optimal  treatment  of  pituitary  carcinoma  remains  unknown.  Multidisciplinary
discussion  among  surgeons,  radiation  oncologists,  medical  oncologists  and
endocrinologists is highly recommended in the management of pituitary carcinoma.
Due  to  the  limited  number  of  observations,  it  is  difficult  to  assess  if  surgery
provides survival benefit. Surgical procedures are very rarely curative in pituitary
carcinoma  due  to  the  local  invasion  of  the  tumor  into  surrounding  structures.
Pituitary carcinomas are usually large tumors exerting mass effects.  Surgery can
potentially  relieve  compressive  symptoms  and  symptoms  of  excess  hormone
secretion[27]. Some may argue against surgery based on one report hypothesizing that
surgical manipulation could potentially contribute to metastatic seeding[28]. In general,
given  the  paucity  of  clinical  trials  to  guide  management  and  limited  treatment
options, surgery should be discussed with patients who are medically operable with
tumors that are surgically resectable. The European Society of Endocrinology (ESE)
guidelines recommend discussion with an expert neurosurgeon regarding surgery
prior to consideration of other treatment options[29].
Radiation  has  been  used  extensively  to  treat  primary  sellar  tumor  and/or
metastatic lesions to achieve local control of the disease. It can be administered in the
adjuvant setting or to patients who are not surgery candidates[30,31]. Both fractionated
external beam radiation therapy (EBRT) and stereotactic radiosurgery are effective in
pituitary tumors. One retrospective study demonstrated an improved progression-
free survival (PFS) in patients with clinically non-functioning pituitary tumors who
received adjuvant radiation versus those who did not (10 year PFS: 93% vs 68%, 15
year PFS:  93% vs  33%, P  <  0.00005)[32].  However,  at  present,  there are no data to
suggest that radiotherapy improves survival in pituitary carcinoma[33]. Limitations of
radiation mainly include long-term hypopituitarism and radiation necrosis in the
temporal  lobes  and other  nearby brain areas,  especially  with maximal  EBRT.  In
addition, there is an increased risk of malignant brain tumors (RR 3.34, 95%CI: 1.06-
10.6) or meningioma (RR 4.06, 95%CI: 1.51-10.9), particularly in patients treated with
radiation before the age of 30 years[34]. Balancing the potential benefits and risks, ESE
suggests that adjuvant radiotherapy should be considered in the setting of a clinically
relevant  invasive  tumor  remnant  with  pathologic  markers  strongly  indicating
aggressive behavior. Importantly, treatment decision should be discussed with an
expert radiation oncologist taking into account tumor size/location, pathology, prior
radiotherapy and dose[29].
There  is  no  consensus  on a  standardized protocol  for  chemotherapy.  Various
combinations including TMZ, cisplatin, carboplatin, etoposide, CCNU, procarbazine,
dacarbazine,  paclitaxel,  vincristine,  methotrexate,  cyclophosphamide,  and
doxorubicin have been used[15].  Among these,  TMZ is  the most  widely used and
appears to be effective. The first patient with pituitary tumor treated with TMZ was
reported in 2006[35,36]. TMZ is a lipophilic alkylating agent that methylates guanine-rich
areas of DNA and leads to DNA double strand breaks and apoptosis. It has been used
extensively in  the treatment  of  glioblastoma with success.  It  was reported,  with
confirmation by IHC and electron microscopy techniques[36], that TMZ could induce
apoptosis  in  pituitary adenomas.  In a  meta-analysis  of  54 patients  with atypical
pituitary adenoma (per previous WHO classification) and pituitary carcinoma, the
objective  response  rate  was  48.4% and the  clinical  benefit  rate  (including stable
disease) was 80%[4]. There was a trend toward benefit from long-term TMZ treatment,
but optimal treatment duration remains unresolved. The 5-year overall survival (OS)
was 57.4% for atypical pituitary adenoma treated with TMZ and 56.2% for pituitary
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carcinoma[4]. OS of pituitary carcinoma prior to the introduction of TMZ was about 2
years based on historical data[3], suggesting an improvement in survival using TMZ.
Negative/ low-level of MGMT IHC staining was strongly associated with response to
TMZ in patients with atypical pituitary adenoma/ pituitary carcinoma[37]. The benefit
of TMZ is modest but still significant given the aggressiveness and poor prognosis of
pituitary carcinoma. Another French study investigated 43 patients with aggressive
pituitary adenomas and pituitary carcinomas who received TMZ treatment and found
a 51.2% response rate with an improved survival among responders compared with
non-responders (median survival, 44 mo vs 16 mo, P = 0.002)[38].
In 2016,  the ESE published a survey on 166 patients  with aggressive pituitary
tumors  or  pituitary  carcinoma.  157  received  TMZ as  first-line  chemotherapy,  7
patients  received other  cytotoxic  or  biological  therapies,  and 2  received peptide
receptor radionuclide therapy (PRRT)[39]. The rationale of using PRRT is based on the
expression  of  somatostatin  receptors  in  all  subtypes  of  pituitary  adenomas,
functioning and non-functioning. In 2 reports, out of 6 patients treated with PRRT,
one had a partial/ complete response, one demonstrated stable disease, and the other
4 progressed on therapy[40,41]. All patients received either 68Ga-DOTATATE PET-CT or
octreotide  scan  to  establish  positive  somatostatin  receptor  status  prior  to  PRRT
treatment. This, although with a small sample size, suggests potential value of PRRT
in the management of pituitary carcinoma.
Additionally, TMZ in combination with capecitabine (CAPTEM) has been studied.
One patient with a highly aggressive, invasive corticotroph tumor who has failed
conventional medical, surgical and radiation therapies, received capecitabine 1000 mg
twice daily on day 1-14 plus TMZ 200 mg/m2  per day on day 10-14 administered
every 28 d[42]. The patient responded well with a more than > 95% decrease in ACTH
level (1874 pg/mL to 85 pg/mL) after 4 cycles of treatment, but progressed 4 weeks
later. Another case series included a total of 4 patients with corticotroph pituitary
tumors who were treated with CAPTEM, and showed duration of response varying
between 5.5 mo to > 45 mo, with 2 of 4 patients demonstrating a complete response[43].
It was proposed that sequential pretreatment with capecitabine may potentiate the
cytotoxicity of TMZ, hence the unique design of this regimen is that TMZ was not
started on day 1, but day 10 of the cycle. Complete response was usually not observed
in patients  treated with TMZ alone.  Therefore,  it  is  significant  to  demonstrate  a
complete regression of disease in 2 out of 4 patients, supporting the theoretic basis
that the addition of capecitabine potentiates cytotoxicity of TMZ. In the ESE survey,
there  were  3  cases  in  which  TMZ  was  administered  as  first-line  treatment  in
combination with capecitabine. One achieved a partial response, one demonstrated
stable disease and the other had progressive disease[29]. Currently, the ESE does not
think there is enough evidence to support upfront TMZ in combination with other
chemotherapies[29].
In patients  with rapid tumor growth who have not  reached maximal doses of
radiotherapy, ESE recommends the "Stupp protocol", commonly used in glioblastoma.
Here, TMZ is utilized as a radio-sensitizing agent at 75 mg/m2 per day concomitant
with 6 wk of fractionated EBRT, followed by TMZ monotherapy at 150-200 mg/m2 for
5 d out of 28-d cycles. In a total of 17 cases reported in the literature, the response rate
was 76%[38,44-46], higher than reported with TMZ alone, suggesting additional clinical
benefit when concurrent chemoradiation is applied.
There are other chemotherapies that have been used in case reports like CCNU plus
fluorouracil (5-FU), cisplatin/carboplatin plus etoposide, but these are less validated
compared to TMZ containing regimens. Recently, a pediatric patient treated with the
combination of carboplatin, leucovorin and 5-FU, achieved a complete radiographic
response and improvement of clinical Cushing’s disease[47].
The use of targeted therapy has been explored, but findings remain inconclusive.
Upregulation  of  Raf/MEK/ERK  and  PI3K/Akt/mTOR  pathways  and  vascular
endothelial growth factor (VEGF) expression have been associated with pituitary
tumorigenesis. VEGF levels were higher in pituitary carcinoma than those in pituitary
adenoma[48,49].  Bevacizumab,  an  anti-VEGF antibody,  has  been used in  a  limited
number of cases to treat aggressive pituitary adenoma or pituitary carcinoma[50]. Ortiz
and colleagues used bevacizumab in a patient with progressive disease on TMZ and
achieved long-term disease  control  for  at  least  26  mo[51].  Bevacizumab was  also
administered concurrently with radiation and TMZ. Touma reported a patient who
was  treated  post-operatively  with  TMZ  at  75  mg/m2  daily  with  radiation  and
bevacizumab at 10 mg/kg biweekly followed by 12 cycles of TMZ at 200 mg/m2 for
five days out of each 28-d cycle. The patient had no evidence of recurrent disease
more than 5 years of follow-up[50]. Newer drugs including sunitinib (a multikinase
inhibitor),  Axitinib  (a  VEGFR  inhibitor),  Everolimus  (an  mTOR  inhibitor),  and
Lapatinib (a EGFR/HER2 inhibitor),  have been reported in cases and studied in
clinical trials.
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CONCLUSION
In conclusion, pituitary carcinoma is a rare neoplasm with poor prognosis that is
difficult  to diagnose and treat.  The small  number of cases restricts  our ability to
design randomized clinical trials. Therefore, management of this cancer has largely
been  dependent  on  information  derived  from  case  series  or  retrospective
observations. Because clinical presentation and the interval between the diagnoses of
pituitary adenoma and carcinoma are variable, a high index of suspicion is required
to establish a diagnosis of pituitary carcinoma. This paper highlights the need for
specific  molecular biomarkers and comprehensive genomic profiling to facilitate
diagnosis of pituitary carcinoma. Treatment is not standardized, and a multi-modality
approach including endocrinologist, neurosurgeon, radiation oncologist and medical
oncologist  is  highly  recommended.  Several  regimens  have  shown  activities  in
pituitary carcinoma with the most evidence supporting upfront TMZ, or TMZ plus
radiation or capecitabine in selected cases. Targeted therapy and PRRT are promising
areas for future research.
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